CORT Announces FDA Approval of Lifyorli Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer, 35% OS Reduction, 16.0-Month Median Survival
Corcept Therapeutics Inc. · PHARMACEUTICAL PREPARATIONS · Now $70.44
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS